Tag: Caribou Biosciences

March 8, 2018

4 Gene Editing Technologies Explained

We look at four types of gene editing currently in clinical trials, as well as the pros and cons of...
October 5, 2017

4 Gene Therapy Stocks to Watch in 2017

At the halfway mark of 2017, here's a look at how these four gene therapy companies are performing so far...
February 15, 2017

The CRISPR-Cas9 Patent Dispute

The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
January 16, 2017

Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research

Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today...
December 16, 2016

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a...
September 6, 2016

BIO Investor Forum 2016 Programming Announced

WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) today announced programming for the 15th annual BIO Investor Forum. Held on October 18-19 at the...
March 10, 2016

After Hot IPO Editas Medicine Bogged Down by CRISPR/Cas9 Legal Issues

Editas Medicine's share price went on a tear following its IPO in February. In the last two days, however, it's...